Abstract:e21055 Background: Second-line chemotherapy alone, such as docetaxel, is standard of care for patients (pts) with advanced NSCLC, but the efficacy is poor. Anti-angiogenic drugs plus chemotherapy had shown to significantly prolong progression-free survival (PFS) in advanced NSCLC (REVEL and LUME-LUNG1). The REVEL trial had demonstrated that East Asian pts with advanced NSCLC receiving docetaxel (60 mg/m 2 , not 75mg/m 2 ) and ramucirumab had a better safety profile. Anlotinib, a novel oral multitarget tyrosine kinase inhibitor, significantly improved PFS and overall survival (OS) of advanced NSCLC in the ALTER0303 trial. In the phase I study, 10mg (QD, d1 to 14 of a 21-day cycle) was identified as the maximum tolerated dose (MTD) of anlotinib when combined with docetaxel (60mg/m 2 ) by a 3+3 dose de-escalation exploration. Here, we presented the updated efficacy and safety of anlotinib plus docetaxel versus docetaxel as second-line treatment for driver-negative advanced NSCLC in the phase II study. Methods: This open-label, multicenter, randomized phase II study enrolled advanced NSCLC pts who had progressed after first-line platinum-based chemotherapy, without sensitizing EGFR/ALK/ROS1 alterations, and with ECOG PS 0-1. Eligible pts were randomized 2:1 to receive anlotinib (10mg, p.o, QD, d1 to 14 of a 21-day cycle) plus docetaxel (60mg/m 2 , q3w, 4-6 cycles) (A+D arm) or docetaxel (60mg/m 2 , q3w, 4-6 cycles) alone (D arm) until disease progression or unacceptable toxicity. The primary endpoint was PFS. Secondary endpoints included the objective response rate (ORR), the disease control rate (DCR), OS and safety. Results: From Jun. 2019 to Dec. 2020, 36 pts were enrolled, 24 pts (median age: 63.0, squamous cell carcinoma: 50.0%, ECOG PS 1: 87.5%) in the A+D arm and 12 pts (median age: 60.0, squamous cell carcinoma: 50.0%, ECOG PS 1: 83.3%) in the D arm. As of Jan. 20, 2021, the median PFS were 6.2 months (95% Cl: 0.00-12.82) in the A+D arm vs 1.4 months (95% Cl: 0.71-2.09) in the D arm (HR: 0.30; 95% Cl: 0.11-0.78, p = 0.007), which remain immature because of the shorter follow-up time. The median OS was not reached. For tumor response, 32 pts were evaluable. The ORR was 27.3% in the A+D arm vs 0% in the D arm (p = 0.142), and the A+D arm showed a significantly higher DCR than the D arm (100.0% vs 50.0%, p = 0.001). Grade 3/4 treatment-related adverse events (TRAEs) occurred in 33.3% (A+D arm) and 0.0% (D arm). The most commonly reported grade 3/4 TRAEs in the A+D arm included neutropenia (8.3%, 2/24), leukopenia (8.3%, 2/24), oral mucositis (8.3%, 2/24) and hypertension (8.3%, 2/24). No grade 5 TRAEs or deaths were observed. Conclusions: Anlotinib plus docetaxel continues to show the better clinical benefit as second-line treatment for driver-negative advanced NSCLC. The safety profile was manageable and consistent with previously reported studies. The longer follow-up time is required. Clinical trial information: NCT03726736.

A Multi-Center Phase II Study of Nintedanib As Second-Line Therapy for Patients with Advanced Non-Small-cell Lung Cancer in China.

A Multicenter, Open-Label Phase Ib/II Study of Cadonilimab (anti PD-1 and CTLA-4 Bispecific Antibody) Monotherapy in Previously Treated Advanced Non-Small-cell Lung Cancer (AK104-202 Study).

Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer

P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population with Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy As 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)

Phase Ⅱ Trial of Gefitinib in Female Patients with Previously Treated Advanced Non-Small Cell Lung Cancer

The efficacy and safety profile of anlotinib plus docetaxel as second-line treatment in advanced non-small cell lung cancer.

A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib Vs Chemotherapy Alone As Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer

Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.

Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): Updated results from a phase I/II study.

1335P Updated Results from a Phase I/II Study of Anlotinib Plus Docetaxel Vs Docetaxel As Second-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

1376P Anlotinib Combination with Docetaxol for Patients with Previously Treated Advanced Non-Small Cell Lung Cancer: A Phase II, Single-Arm Trial

A Phase II Trial of Anlotinib Plus EGFR-TKIs in Advanced Non-Small Cell Lung Cancer with Gradual, Oligo, or Potential Progression after EGFR-TKIs Treatment (CTONG-1803/ALTER-L001)

Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial

An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)

Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel As First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung - A Multicenter, Open-label, Randomized, Phase III Trial.

A Phase II Trial of Gefitinib As Maintenance Therapy after First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in China

Intercalating and Maintenance Use of Gefitinib Plus Chemotherapy Versus Chemotherapy Alone in Selected Advanced Nsclc(Iscan,Ctong-1102): A Multicentre, Open-Label, Randomised, Phase 3 Study.